JUNS JUPITER NEUROSCIENCES, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1679628 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-86.1%
TTM EPS YoY71.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-673.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets171.6%
Debt / equity—
Current ratio0.49x
Interest coverage-39.17x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-253.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $21,796 | $0 | — |
| Cost of revenue | $4,231 | — | — |
| Gross profit | $17,565 | — | — |
| R&D expense | $2.09M | $492,660 | $954,793 |
| SG&A expense | $6.84M | $2.60M | $2.92M |
| Operating income | -$8.91M | -$3.09M | -$3.87M |
| Interest expense | $66,020 | $248,366 | $218,705 |
| Net income | -$8.64M | -$2.44M | -$4.78M |
| EPS (basic) | -0.25 | -0.08 | -0.18 |
| EPS (diluted) | -0.25 | -0.08 | -0.18 |
| Weighted avg. shares (diluted) | 34.63M | 28.78M | 26.41M |
| Balance sheet | |||
| Cash & equivalents | $3.79M | $3.77M | $28,478 |
| Receivables | $2,637 | — | — |
| Inventory | $159,790 | — | — |
| Current assets | $4.82M | $4.65M | $28,739 |
| Total assets | $5.56M | $6.20M | $148,592 |
| Current liabilities | $7.40M | $2.01M | $5.77M |
| Total liabilities | $7.40M | $2.03M | $5.95M |
| Shareholders' equity | -$1.83M | $4.17M | -$5.80M |
| Shares outstanding | 459,286 | 33.10M | 26.53M |
| Cash flow statement | |||
| Operating cash flow | -$5.41M | -$3.91M | -$480,953 |
| Financing cash flow | $5.43M | $7.65M | $445,000 |
| Stock-based compensation | $2.42M | $1.84M | $1.20M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.